|
1
|
Guerrier Y and Dejean Y: Cancer of larynx
and hypopharynx in women [M]UICC Manual of Clinical Oncology. 9.
John Wiley & Sons, Ltd.; pp. 542–558. 2015
|
|
2
|
Agra IM, Ferlito A, Takes RP, Silver CE,
Olsen KD, Stoeckli SJ, Strojan P, Rodrigo JP, Gonçalves Filho J,
Genden EM, et al: Diagnosis and treatment of recurrent laryngeal
cancer following initial nonsurgical therapy. Head Neck.
34:727–735. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Saki N, Saki G, Abdoulhassan S, Rahim F,
Mostofi NE and Soheila N: Effect of smoking tobacco in the etiology
of cancer of larynx in Khuzestan. Jentashapir Journal of Health
Research. 2:1–9. 2011.
|
|
4
|
Xie ZN, Ji CY, Chen JC, Wang YN, Guan LQ,
Li HT, Zhang M and Yang JH: The influence of
pSilencer2.0-c-Met-siRNA on human cancer of larynx Hep-2 cells
growth in nude mice. J Otolaryngol Ophthalmol Shandong Univ.
23:5–7. 2009.
|
|
5
|
Tarnawski R, Skladowski K and Maciejewski
B: Prognostic value of hemoglobin concentration in radiotherapy for
cancer of supraglottic larynx. Int J Radiat Oncol Biol Phys.
38:1007–1011. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wynder EL, Bross IJ and Day E: A study of
environmental factors in cancer of the larynx. Cancer. 9:86–110.
1956. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Moore I: Intrinsic cancer of the larynx
and the operation of Laryngo-Fissure, with a description of some
new instruments specially designed for improving the technique.
Multibody Syst Dyn. 31:191–240. 2013.
|
|
8
|
Pan D: The hippo signaling pathway in
development and cancer. Dev Cell. 19:491–505. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Cai J, Zhang N, Zheng Y, de Wilde RF,
Maitra A and Pan D: The Hippo signaling pathway restricts the
oncogenic potential of an intestinal regeneration program. Genes
Dev. 24:2383–2388. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ramos A and Camargo FD: The Hippo
signaling pathway and stem cell biology. Trends Cell Biol.
22:339–346. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Mo JS, Park HW and Guan KL: The Hippo
signaling pathway in stem cell biology and cancer. EMBO Rep.
15:642–656. 2014.PubMed/NCBI
|
|
12
|
Yue T, Tian A and Jiang J: The cell
adhesion molecule echinoid functions as a tumor suppressor and
upstream regulator of the Hippo signaling pathway. Dev Cell.
22:255–267. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kwon Y, Vinayagam A, Sun X, Dephoure N,
Gygi SP, Hong P and Perrimon N: The Hippo signaling pathway
interactome. Science. 342:737–740. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Gao PF, Cui PC, YanYan R, et al: Early
vocal cords cancer and precancerosis of larynx treated with Nd: YAP
laser under the laryngoscope and rigid endoscope. J Mod Oncol.
1:191–195. 2009.
|
|
15
|
Li D, You HH, Jia YJ, Guo JD and Du HL:
Association of C722T polymorphism in XRCC3 gene with larynx cancer:
A meta-analysis. Tumor Biol. 35:5427–5430. 2014. View Article : Google Scholar
|
|
16
|
Kim M, Kim M, Lee S, Kuninaka S, Saya H,
Lee H, Lee S and Lim DS: cAMP/PKA signalling reinforces the
LATS-YAP pathway to fully suppress YAP in response to actin
cytoskeletal changes. EMBO J. 32:1543–1555. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wang S, Li H, Wang G, Zhang T, Fu B, Ma M,
Quan Z and Chen G: Yes-associated protein (YAP) expression is
involved in epithelial-mesenchymal transition in hepatocellular
carcinoma. Clin Transl Oncol. 18:172–177. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Hu X, Xin Y, Xiao Y and Zhao J:
Overexpression of YAP1 is correlated with progression, metastasis
and poor prognosis in patients with gastric carcinoma. Pathol Oncol
Res. 20:805–811. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Chan SW, Lim CJ, Chong YF, Pobbati AV,
Huang C and Hong W: Hippo pathway-independent restriction of TAZ
and YAP by angiomotin. J Biol Chem. 286:7018–7026. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Gilgenkrantz H: The world according to
YAP: A continuous cross-talk between Wnt and Hippo pathways. Med
Sci (Paris). 29:868–874. 2013.(In French). View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ma L: Abstract BS2-2: Targeting the
LIFR-Hippo-YAP pathway as an anti-metastatic strategy. Cancer Res.
75:BS2-2. 2015. View Article : Google Scholar
|
|
22
|
Chen D, Sun Y, Wei Y, Zhang P, Rezaeian
AH, TeruyaFeldstein J, Gupta S, Liang H, Lin HK, Hung MC and Ma L:
LIFR is a breast cancer metastasis suppressor upstream of the
Hippo-YAP pathway and a prognostic marker. Nat Med. 18:1511–1517.
2012. View
Article : Google Scholar : PubMed/NCBI
|
|
23
|
Hergovich A: YAP-Hippo signalling
downstream of leukemia inhibitory factor receptor: Implications for
breast cancer. Breast Cancer Res. 14:3262012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Li HX, He N and Zheng H: Research progress
on correlation between YAP and tumor stem cells. Chin J Clin Oncol.
728–731. 2015.
|
|
25
|
Bohl CR, Harihar S, Denning WL, Sharma R
and Welch DR: Metastasis suppressors in breast cancers: Mechanistic
insights and clinical potential. J Mol Med (Berl). 92:13–30. 2014.
View Article : Google Scholar : PubMed/NCBI
|
